News

UK biotechnology company NexaBiome Life Sciences Ltd has received continued funding from Scotland's national economic development agency, Scottish Enterprise, to accelerate its breakthrough bacteriophage technology for the treatment of diabetic foot infections (DFIs).

The funding is the second tranche of support in a £125k project to support the development of a stable, room-temperature wound dressing aimed at treating DFIs, a severe complication of diabetes that has been exacerbated by drug-resistant bacteria and which can lead to amputation or death.

The grant supports NexaBiome’s commitment to developing alternative medicines to tackle antimicrobial resistance (AMR).

Dr. Jason Clark, Chief Executive Officer at NexaBiome, said: “We’re grateful for Scottish Enterprise’s ongoing support. This will help accelerate the development of our formulation for DFIs, which has the potential to transform patient care and outcomes. Every day, we move closer to making accessible phage-based treatments a reality.”

Jane Martin Managing Director of Innovation and Investment at Scottish Enterprise said: “We are proud to have supported Nexabiome over the years with funding and advice as the company has developed its life-saving diabetic treatment.

“By focussing on high growth industries Scottish Enterprise can help companies to scale and transform Scotland’s economy, drive economic growth and strengthen Scotland’s reputation as a leader in health innovation.”

AMR is listed as one of the most pressing global health challenges, with the World Health Organisation predicting that drug-resistant diseases could cause up to 10 million deaths a year by 2050.

NexaBiome’s human health programme is focused on expanding the use of phage therapy to tackle drug-resistant bacterial infections, using its patented phage stabilising bacteriophage technology. The company is working to take phage therapy through clinical trials to develop licensed medicines that can be used as an alternative or complementary treatment to antibiotics.

HiiROC, a leading innovator in clean hydrogen production, has received grant support from Scotland’s national economic development agency, Scottish Enterprise, towards a project that could transform the aviation industry.

A Scottish clean-tech company developing small modular wind turbines that can be deployed in almost any location has secured £865,000 in seed funding, led by TRICAPITAL Angels

Historic agreement with UAE signed

Supporting future Grangemouth industries

Biotech innovator set to scale-up its sustainable algal Omega 3 production to meet rising demand from petfood and aquaculture markets

PXN Ventures, the fastest-growing venture-focused investment firm outside London and the South East, joins existing shareholders to support Orbital’s commercial tidal-stream projects, following new tidal energy licences in Canada

Pioneering molecular diagnostics company MI:RNA, which uses biomarkers and advanced modelling to diagnose veterinary disease earlier, has reached a growth milestone with the completion of an oversubscribed funding round.

A pioneering digital platform, dedicated to trauma prevention and management for frontline professionals, has secured funding of £1.2m from investors.

Investment comes after surging demand for Rhizocore’s fungal tree health pellets.

1nhaler, a Scotland-based drug delivery device developer, has secured an additional £1.5 million in seed funding to drive development of its novel pop-up cardboard dry powder inhaler (DPI).

Scottish Brain Sciences (SBS), a leading clinical research organisation dedicated to transforming the early detection and treatment of Alzheimer’s disease and other neurodegenerative conditions, has opened a new state-of-the-art clinical research centre at ONE BioHub, Aberdeen.